Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAUVAL is an oral tablet formulation of Rauwolfia serpentina root, a botanical extract traditionally used in Ayurvedic medicine. The product is in pre-launch development under Bausch + Lomb's NDA portfolio. Specific indications and mechanism of action are not yet disclosed in available regulatory data.
Pre-Launch
As a pre-launch asset, RAUVAL offers entry-level opportunity for early-stage brand building and go-to-market planning, with team formation expected closer to approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RAUVAL is a botanical NDA in early development with limited current hiring; career opportunity is tied to approval and commercialization milestones. Professionals joining this program now would participate in foundational regulatory and commercial strategy work for a differentiated botanical asset in the Bausch + Lomb portfolio.
Regulatory Affairs ManagerBrand Manager
Worked on RAUVAL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.